-
Chlorpromazine at the Neuro–Liver Interface
2026-09-15
Chlorpromazine can serve as more than a reference compound in antipsychotic research. This article examines how its receptor pharmacology may support carefully controlled studies of hepatic nanoparticle interactions, while separating established evidence from translational hypotheses and outlining practical validation strategies.
-
FPH1 (BRD-6125) Hepatocyte Enhancer
2026-09-15
A practical, scenario-based guide to using FPH1 (BRD-6125) Hepatocyte Functional Proliferation Enhancer, SKU B3701, in primary human hepatocyte culture and iPS-derived hepatocyte workflows. It covers assay design, dosing, functional readouts, handling, interpretation, and vendor selection without overstating the available evidence.
-
PEGylated Iron Oxide Nanoparticles in the Liver
2026-09-14
This ACS Nano study separates the effects of iron oxide nanoparticle size and PEG chain length on hepatic distribution using 99mTc-SPECT/CT and primary liver-cell assays. Its most important finding is that hepatocytes and stellate cells can contribute substantially to uptake, challenging the assumption that Kupffer cells dominate nanoparticle clearance and providing a more cell-resolved framework for nanomedicine design.
-
Reelin–SFK Signaling in Ketamine Response
2026-09-14
The reference study identifies Reelin–Apoer2–Src family kinase signaling as a permissive pathway for ketamine-induced hippocampal synaptic plasticity and antidepressant-like behavioral effects. Its genetic and pharmacological experiments suggest that preserved baseline NMDA receptor function, rather than acute activation of the pathway by ketamine, may help determine treatment responsiveness.
-
Nicotinamide Riboside Chloride in iPSC-RGC Assays
2026-09-13
Nicotinamide Riboside Chloride (NIAGEN) can serve as a controlled NAD+ metabolism variable in iPSC-derived retinal ganglion cell research. This article connects the compound’s energy biology with reproducible RGC differentiation while separating established evidence from testable assay hypotheses.
-
3-Aminobenzamide: From PARP Biology to Translation
2026-09-12
A translational framework for using 3-Aminobenzamide (PARP-IN-1) to connect PARP-dependent stress biology with vascular, metabolic, and antiviral research while preserving mechanistic rigor, model-specific validation, and appropriate interpretation limits.
-
DAPI Workflows for Cancer Cell Fate Analysis
2026-09-12
DAPI converts nuclear integrity and chromatin morphology into practical readouts for fixed-cell imaging, viability screening, apoptosis-oriented analysis, and flow cytometry. This workflow connects those measurements to microbiome–breast cancer research while clearly separating what DAPI can reveal from what requires molecular or metabolic assays.
-
PBA-Modified PAD4 Inhibitors Block Tumor NETs
2026-09-11
The reference study developed phenylboronic acid-modified PAD4 inhibitors to improve tumor targeting and suppress the PAD4–H3cit–NET pathway. Compound 5i limited tumor growth and lung metastasis in mouse models primarily by acting on neutrophil biology rather than directly killing tumor cells, highlighting a targeted strategy for tumor-microenvironment intervention.
-
Intestinal TM6SF2 and the Gut–Liver Axis in MASH
2026-09-11
The reference study shows that intestinal TM6SF2 protects against metabolic dysfunction-associated steatohepatitis by preserving epithelial barrier function and constraining microbiota- and lipid-mediated signaling. Genetic, microbiota-transfer, and pharmacological experiments connect intestinal TM6SF2 loss to pathobiont enrichment, elevated lysophosphatidic acid, hepatic lipid accumulation, and inflammation.
-
Simvastatin (Zocor) for Translational Cell Assays
2026-09-10
Simvastatin (Zocor) connects cholesterol-biosynthesis studies with apoptosis, cell-cycle, and high-content phenotyping workflows. This bench-focused guide shows how to manage its prodrug biology, solvent limitations, dose selection, and cross-cell-line assay transfer.
-
Of Chloroquine and COVID-19: Evidence and Limits
2026-09-10
Touret and de Lamballerie’s commentary placed early enthusiasm for chloroquine against the broader antiviral literature, showing that cell-culture activity has repeatedly failed to predict clinical benefit. Its central contribution is a translational warning: antiviral effects must be evaluated across animal models, human trials, immune consequences, and safety constraints rather than inferred from in vitro results alone.
-
Nanocarrier-Mediated dsRNA Transdermal Delivery
2026-09-09
Guan and colleagues investigate how a star cationic polymer enables double-stranded RNA to cross the insect cuticle, identifying wax-layer dissolution and reduced chitin-layer resistance as complementary mechanisms. The study provides a mechanistic framework for designing noninvasive RNAi delivery systems while clarifying why cuticle structure, wetting, and carrier–barrier interactions must be considered together.
-
Genotyping Kit for target alleles: PCR-Ready DNA
2026-09-09
Convert insect, fish, tissue, and cell samples into PCR-ready genomic DNA without phenol extraction, spin columns, or overnight processing. APExBIO’s K1026 combines single-tube lysis with a dye-containing 2× PCR Master Mix for practical allele screening and model validation.
-
Sabutoclax: A Pan-Bcl-2 Inhibitor for Apoptosis
2026-09-08
Sabutoclax supports apoptosis-focused studies that distinguish genuine cell killing from simple growth suppression. This guide connects target-level potency, paired viability and death assays, cancer-cell models, and troubleshooting strategies for more interpretable results.
-
Puerarin Activates NO Signaling in Dental Follicle Cells
2026-09-08
The reference study shows that puerarin promotes osteogenic differentiation of rat dental follicle cells while increasing nitric oxide, cGMP, and osteogenic markers. Pharmacological inhibition with L-NMMA reversed these effects, supporting a functional role for nitric oxide pathway modulation in periodontal regeneration research.